News

Battling the Silent Pandemic: India’s Pharma Industry Takes on Antimicrobial Resistance

The country’s pharma industry, known globally as the “pharmacy of the world,” is making significant strides in developing novel drugs to combat AMR. The introduction of breakthrough drugs such as Nafithromycin and Enmetazobactam marks a turning point, highlighting India’s growing leadership in addressing this silent pandemic. Photo Credit: Freepik.com

• By Pooja Chaturvedi Sah
• New Delhi
• Dec 09, 2024

News

Antibiotics have long been celebrated as modern medicine’s ultimate lifesavers. But in recent years, these medical marvels have faced an evolving challenge—bacteria that can mutate, adapt, and resist the very drugs meant to eliminate them. 

This phenomenon, known as antimicrobial resistance (AMR), has turned once-treatable infections into life-threatening conditions. Globally, antibiotic-resistant infections were directly responsible for 1.14 million deaths in 2021, according to The Lancet. 

In India, the situation is particularly alarming, with AMR causing nearly 300,000 deaths in 2019 alone. Each year, around 60,000 newborns in the country succumb to infections that no longer respond to antibiotics. Amid this grim backdrop, Indian pharmaceutical companies have risen to the challenge, offering promising solutions. 

The country’s pharma industry, known globally as the “pharmacy of the world,” is now making significant strides in developing novel drugs to combat AMR. The introduction of breakthrough drugs such as Nafithromycin and Enmetazobactam marks a turning point, highlighting India’s growing leadership in addressing this silent pandemic. 

One of the most notable recent developments comes from Wockhardt, an Indian multinational pharmaceutical company. Wockhardt recently unveiled Nafithromycin, branded as “Miqnaf,” India’s first novel macrolide antibiotic designed to tackle drug-resistant infections. 

Officially launched in November 2024, this drug targets Community-Acquired Bacterial Pneumonia (CABP), a condition that disproportionately affects children, the elderly, and individuals with weakened immune systems. Nafithromycin stands out for its exceptional efficacy, offering ten times the potency of azithromycin, one of the most commonly used antibiotics for respiratory infections. Its three-day treatment regimen significantly shortens recovery times, making it not only more effective but also more convenient for patients. According to Dr. Jitendra Singh, Union Minister of Science and Technology, “Nafithromycin’s development not only addresses a public health crisis but also establishes India as a leader in pharmaceutical innovation.”

Moreover, its safety profile—with fewer side effects and minimal drug interactions—positions it as a breakthrough treatment in the global fight against AMR. The development of Nafithromycin, however, is not an isolated achievement. Indian pharmaceutical firms have been making notable progress in creating drugs that specifically target resistant pathogens. 

Chennai-based Orchid Pharma made headlines earlier this year with the approval of Enmetazobactam by the US Food and Drug Administration (FDA). This injectable drug is engineered to treat severe infections such as urinary tract infections (UTIs), pneumonia, and bloodstream infections. Unlike traditional antibiotics that target the bacteria itself, Enmetazobactam works by neutralizing bacterial enzymes like beta-lactamase, which bacteria use to destroy antibiotics. By binding tightly to these enzymes, Enmetazobactam effectively disarms the bacteria’s defenses, allowing other antibiotics, including carbapenems—the “last-resort” drugs—to do their job without triggering further resistance. This approach not only tackles the immediate infection but also helps preserve the efficacy of existing antibiotics, a critical factor in the battle against AMR.

The potential of these drugs is underscored by rigorous clinical trials. Enmetazobactam was tested across 19 countries with over 1,000 patients and demonstrated remarkable effectiveness in treating resistant infections. Similarly, Nafithromycin achieved a 96.7% clinical cure rate in trials, far surpassing traditional treatments. It also provides eight times the lung exposure and ten times the potency of azithromycin, making it a promising option for treating CABP caused by both typical and atypical bacteria. 

Other Indian pharmaceutical companies are also joining the fight against AMR with innovative solutions in their pipelines. Wockhardt is developing Zaynich, an antibiotic for severe drug-resistant infections, which is currently in Phase III trials and expected to launch by 2025. Meanwhile, Bengaluru-based Bugworks Research, in collaboration with the Geneva-based Global Antibiotic Research and Development Partnership (GARDP), is working on a new class of antibiotics for serious drug-resistant infections. This drug is in the early stages of Phase I trials but holds significant promise for addressing critical healthcare gaps. 

The urgency of these developments cannot be overstated. AMR has been described as a “silent pandemic” that could reverse decades of progress in modern medicine. If left unchecked, it is projected to cause up to 10 million deaths annually by 2050. In India, the crisis is exacerbated by factors such as overuse and misuse of antibiotics, lack of robust infection control measures, and inadequate public awareness. 

A 2023 report by the Indian Council of Medical Research (ICMR) revealed resistance levels as high as 60% for some treatments, underscoring the dire need for new and effective drugs. The development of novel antibiotics like Nafithromycin and Enmetazobactam represents more than just a scientific breakthrough; it is a testament to the power of public-private collaboration. 

Nafithromycin, for instance, was developed with funding from the Biotechnology Industry Research Assistance Council (BIRAC), a public sector enterprise under India’s Department of Biotechnology. BIRAC provided ₹8 crore for Phase III clinical trials, highlighting the critical role of government support in fostering innovation. This collaboration exemplifies how targeted investments and partnerships can address market failures in antibiotic development, an area often neglected by global pharmaceutical companies due to low returns on investment. 

India’s approach to combating AMR extends beyond drug development. The government has implemented a series of measures to promote the judicious use of antibiotics, enhance infection prevention, and strengthen surveillance. 

Initiatives such as the National Action Plan on AMR, the Red Line Campaign to discourage over-the-counter antibiotic sales, and stringent regulations under Schedule H1 of the Drugs Rules are aimed at curbing the misuse of antibiotics. Additionally, international collaborations with organizations like the US Centers for Disease Control and Prevention (CDC), the UK’s Fleming Fund, and the World Health Organization (WHO) have bolstered India’s efforts to address AMR on a global scale. 

India’s leadership in tackling AMR comes at a critical juncture. With no new class of antibiotics introduced globally in over three decades, the emergence of drugs like Nafithromycin and Enmetazobactam offers renewed hope in the fight against resistant infections. These innovations not only save lives but also demonstrate India’s growing capabilities in pharmaceutical research and development. As the country continues to invest in cutting-edge science and strengthen its healthcare infrastructure, it is well-positioned to play a pivotal role in addressing one of the most pressing public health challenges of our time. 

The road ahead will not be without challenges. Antibiotic development is a costly and time-intensive process, often taking over a decade to bring a drug from concept to market. Sustaining these efforts will require continued investments, robust policy support, and global collaboration. Yet, the progress made so far serves as a powerful reminder of what is possible when science, industry, and government come together with a shared purpose. 

India’s fight against AMR is far from over, but the strides it has made offer a blueprint for tackling this global crisis. In the words of Vishwajit Rane, Goa’s Health Minister, “India’s leadership in combating AMR is not just a national priority but a global responsibility.”